Boehringer Ingelheim Abandons Flibanserin, 'Pink Viagra' Drug Research

RoseTracker| Boehringer Ingelheim has abandoned its work on flibanserin, after the US FDA refused approval and requested more research on the drug. We supported the decision but don’t agree that the search for ‘pink Viagra’ should end.

We are probably the only pro-women writers who believe that Boehringer accomplished a positive action for American women, if we choose to learn from their research results.

It was American women who responded the most positively to Boehringer, much more than European women. The reasons for the disparate response underscore our core belief at Anne of Carversville that US women’s loss of libido is tied to morality, obesity, and aging issues rooted in our culture. Read on in Anne’s ‘Sensually Yours’.